DK2134691T3 - Quinolinonderivativer som parp- og tank-inhibitorer - Google Patents
Quinolinonderivativer som parp- og tank-inhibitorerInfo
- Publication number
- DK2134691T3 DK2134691T3 DK08717511.3T DK08717511T DK2134691T3 DK 2134691 T3 DK2134691 T3 DK 2134691T3 DK 08717511 T DK08717511 T DK 08717511T DK 2134691 T3 DK2134691 T3 DK 2134691T3
- Authority
- DK
- Denmark
- Prior art keywords
- parp
- quinolinonderivatives
- inhibitors
- tank
- tank inhibitors
- Prior art date
Links
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89368007P | 2007-03-08 | 2007-03-08 | |
| EP07103788 | 2007-03-08 | ||
| PCT/EP2008/052764 WO2008107478A1 (en) | 2007-03-08 | 2008-03-07 | Quinolinone derivatives as parp and tank inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2134691T3 true DK2134691T3 (da) | 2012-05-07 |
Family
ID=38421149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08717511.3T DK2134691T3 (da) | 2007-03-08 | 2008-03-07 | Quinolinonderivativer som parp- og tank-inhibitorer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8299256B2 (da) |
| EP (1) | EP2134691B1 (da) |
| JP (1) | JP5545955B2 (da) |
| AT (1) | ATE542799T1 (da) |
| AU (1) | AU2008223793B2 (da) |
| CA (1) | CA2678248C (da) |
| DK (1) | DK2134691T3 (da) |
| ES (1) | ES2381446T3 (da) |
| HR (1) | HRP20120346T1 (da) |
| SI (1) | SI2134691T1 (da) |
| WO (1) | WO2008107478A1 (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ546990A (en) | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| NZ546991A (en) | 2003-11-20 | 2010-01-29 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors |
| CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| WO2006003147A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
| JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体 |
| EP1906948A4 (en) | 2005-07-18 | 2010-03-17 | Bipar Sciences Inc | TREATMENT OF CANCER |
| AU2007292306A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| WO2009053373A1 (en) | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| WO2009064738A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| DK2271626T3 (da) * | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinoner og tetrahydrocyclopentaquinolinoner som inhibitorer af polymerisering af parp og tubulin |
| WO2009118384A1 (en) * | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| JP5439745B2 (ja) * | 2008-05-27 | 2014-03-12 | 宇部興産株式会社 | ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法 |
| CN102149379A (zh) * | 2008-07-10 | 2011-08-10 | 安吉翁生物医药有限公司 | 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物 |
| US20110098304A1 (en) * | 2008-10-22 | 2011-04-28 | Bijoy Panicker | Small molecule inhibitors of PARP activity |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| CN115778934A (zh) | 2012-01-20 | 2023-03-14 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
| US9339503B2 (en) | 2012-02-09 | 2016-05-17 | Merck Patent Gmbh | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors |
| HRP20160908T1 (hr) | 2012-03-28 | 2016-09-23 | Merck Patent Gmbh | Biciklički derivati pirazinona |
| SG11201406997WA (en) * | 2012-05-04 | 2014-11-27 | Merck Patent Gmbh | Pyrrolotriazinone derivatives |
| CN104507912B (zh) | 2012-08-08 | 2016-09-28 | 默克专利股份公司 | (氮杂-)异喹啉酮衍生物 |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| MX362855B (es) | 2012-09-26 | 2019-02-20 | Merck Patent Gmbh | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). |
| US9719970B2 (en) | 2012-11-30 | 2017-08-01 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin D metabolites |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| RU2016147727A (ru) | 2014-05-07 | 2018-06-08 | Мерк Патент Гмбх | Гетероциклилбутанамидные производные |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| DK3356345T3 (da) | 2015-09-30 | 2024-02-12 | Max Planck Gesellschaft | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer |
| CR20200263A (es) | 2017-12-13 | 2020-07-26 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
| JP2022510368A (ja) | 2018-12-03 | 2022-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | タンキラーゼのインヒビターとしての４－ヘテロアリールカルボニル－ｎ－（フェニルまたはヘテロアリール）ピペリジン－１－カルボキサミド |
| MX2021012250A (es) | 2019-04-11 | 2022-01-18 | Angion Biomedica Corp | Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol. |
| TWI837403B (zh) | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| AU2022280845A1 (en) | 2021-05-24 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| CN118382624A (zh) * | 2021-12-17 | 2024-07-23 | 凯复(苏州)生物医药有限公司 | Parp抑制剂、包含其的药物组合物及其用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| KR20250103773A (ko) | 2022-11-23 | 2025-07-07 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB732581A (en) | 1952-01-18 | 1955-06-29 | Ciba Ltd | Manufacture of hydrazine compounds |
| DE1006423B (de) | 1952-01-18 | 1957-04-18 | Ciba Geigy | Verfahren zur Herstellung von Hydrazinophthalazinen |
| US3274194A (en) | 1963-03-29 | 1966-09-20 | Miles Lab | Quinazolinedione derivatives |
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| US3919425A (en) | 1971-04-09 | 1975-11-11 | Miles Lab | Method of producing vasodilation using certain 3-substituted-quinazoline derivatives |
| BE792206A (da) | 1971-12-02 | 1973-06-01 | Byk Gulden Lomberg Chem Fab | |
| US3879393A (en) | 1973-06-18 | 1975-04-22 | Miles Lab | Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones |
| FR2436781A1 (fr) | 1978-09-19 | 1980-04-18 | Berri Balzac | Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique |
| US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| JPS5976082A (ja) | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| JPS60120872A (ja) | 1983-12-01 | 1985-06-28 | Kyowa Hakko Kogyo Co Ltd | 新規なヘテロ環状化合物及び強心剤 |
| MA20387A1 (fr) | 1984-03-26 | 1985-10-01 | Janssen Pharmaceutica Nv | Pyridazinamines utiles comme agents anti-viraux et procede pour leur preparation |
| US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
| DK623586A (da) | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| US5231184A (en) | 1987-11-23 | 1993-07-27 | Janssen Pharmaceutica N.V. | Pridazinamine derivatives |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| GB8827822D0 (en) | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| US5374637A (en) | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
| EP0391462A1 (en) | 1989-04-05 | 1990-10-10 | Janssen Pharmaceutica N.V. | Synergistic compositions containing ketanserin |
| US5160727A (en) | 1990-02-13 | 1992-11-03 | Warner-Lambert Company | Tumor cell sensitization method using quinazolinedione derivatives |
| IE913473A1 (en) | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
| JP3333878B2 (ja) | 1992-04-23 | 2002-10-15 | メレルダウファーマスーティカルズ インコーポレイテッド | セロトニン５ｈｔ２拮抗剤としての４‐イミドメチル‐１‐［２’フェニル‐２’オキソエチル‐］ピペリジン類，それらの製法及び治療用途 |
| TW294595B (da) | 1992-11-20 | 1997-01-01 | Janssen Pharmaceutica Nv | |
| CA2118117A1 (en) | 1993-02-18 | 1994-08-19 | Shigeki Fujiwara | Adenosine uptake inhibitor |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| TW445263B (en) | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
| JPH107572A (ja) | 1996-06-17 | 1998-01-13 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| EP0999208A4 (en) | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6407116B1 (en) | 1997-09-16 | 2002-06-18 | Takeda Chemical Industries, Inc. | Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| JP2000191659A (ja) | 1999-01-04 | 2000-07-11 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
| EP1147112B1 (en) | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| US7265115B2 (en) | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| CN1703403A (zh) | 2000-10-02 | 2005-11-30 | 詹森药业有限公司 | 趋代谢的谷氨酸盐受体拮抗剂 |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| KR100957516B1 (ko) | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2ｈ-프탈라진-1-온 및 이것의 사용 방법 |
| CA2465491A1 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| NZ535438A (en) | 2002-03-29 | 2006-08-31 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| ATE540928T1 (de) | 2002-11-22 | 2012-01-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und ihre medizinische verwendung |
| US20050075364A1 (en) | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
| NZ546991A (en) * | 2003-11-20 | 2010-01-29 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors |
| NZ546990A (en) * | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| PT1689715E (pt) | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Inibidores da tubulina |
| JP4806353B2 (ja) * | 2003-12-05 | 2011-11-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン |
| ES2565581T3 (es) | 2003-12-10 | 2016-04-05 | Janssen Pharmaceutica Nv | 2-Quinolinonas/2-quinoxalinonas 6-(hetero)ciclohexilalquil sustituidas como inhibidores de poli(ADP-ribosa) polimerasa |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2005117876A1 (en) | 2004-06-01 | 2005-12-15 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
| JP5100376B2 (ja) * | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体 |
| WO2006003147A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
| CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| NZ560712A (en) | 2005-02-17 | 2010-12-24 | Synta Pharmaceuticals Corp | (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders |
| CN101166732B (zh) | 2005-04-28 | 2013-04-17 | 田边三菱制药株式会社 | 氰基吡啶衍生物及其作为药物的应用 |
| CN101316592A (zh) | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| CA2640678C (en) | 2006-02-03 | 2015-03-31 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| EP2468748B1 (en) | 2006-02-15 | 2016-05-25 | AbbVie Inc. | Pyrazoloquinolones are potent parp inhibitors |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| JP5545955B2 (ja) * | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| US8153633B2 (en) | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
-
2008
- 2008-03-07 JP JP2009552213A patent/JP5545955B2/ja not_active Expired - Fee Related
- 2008-03-07 US US12/529,142 patent/US8299256B2/en active Active
- 2008-03-07 ES ES08717511T patent/ES2381446T3/es active Active
- 2008-03-07 DK DK08717511.3T patent/DK2134691T3/da active
- 2008-03-07 AT AT08717511T patent/ATE542799T1/de active
- 2008-03-07 SI SI200830607T patent/SI2134691T1/sl unknown
- 2008-03-07 HR HRP20120346AT patent/HRP20120346T1/hr unknown
- 2008-03-07 AU AU2008223793A patent/AU2008223793B2/en not_active Ceased
- 2008-03-07 CA CA2678248A patent/CA2678248C/en active Active
- 2008-03-07 WO PCT/EP2008/052764 patent/WO2008107478A1/en not_active Ceased
- 2008-03-07 EP EP08717511A patent/EP2134691B1/en active Active
-
2012
- 2012-09-14 US US13/617,686 patent/US8778966B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100168065A1 (en) | 2010-07-01 |
| US8299256B2 (en) | 2012-10-30 |
| US8778966B2 (en) | 2014-07-15 |
| WO2008107478A1 (en) | 2008-09-12 |
| AU2008223793B2 (en) | 2012-08-23 |
| HRP20120346T1 (hr) | 2012-05-31 |
| CA2678248A1 (en) | 2008-09-12 |
| WO2008107478A8 (en) | 2008-10-23 |
| JP5545955B2 (ja) | 2014-07-09 |
| CA2678248C (en) | 2016-06-28 |
| EP2134691B1 (en) | 2012-01-25 |
| SI2134691T1 (sl) | 2012-06-29 |
| US20130018017A1 (en) | 2013-01-17 |
| EP2134691A1 (en) | 2009-12-23 |
| ATE542799T1 (de) | 2012-02-15 |
| AU2008223793A1 (en) | 2008-09-12 |
| ES2381446T3 (es) | 2012-05-28 |
| JP2010520262A (ja) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2134691T1 (sl) | Derivati kvinolina kot PARP in TANK inhibitorji | |
| MX2010010406A (es) | Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina. | |
| ATE547415T1 (de) | Inhibitoren der wechselwirkung zwischen mdm2 und p53 | |
| ECSP10010722A (es) | Compuestos orgánicos | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| ATE470665T1 (de) | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
| EA201070278A1 (ru) | Ингибиторы гамма-секретазы | |
| EA201270590A1 (ru) | Ингибиторы акт | |
| BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| CY1109331T1 (el) | Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης | |
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
| MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| CY1110900T1 (el) | Χημικες ενωσεις | |
| CY1108275T1 (el) | Χημικες ενωσεις | |
| UA112428C2 (uk) | Пестицидні композиції і пов'язані з ними способи | |
| EA201170832A1 (ru) | Пуриновые соединения | |
| EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы | |
| EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
| CR20140135A (es) | Nuevos derivados de aril-quinolina | |
| PT2310356E (pt) | Derivados de adamantildiamida e a sua utilização |